期刊文献+

沙库巴曲缬沙坦致不良反应的文献分析 被引量:1

Literature analysis of adverse drug reactions induced by sacubitril/valsartan
下载PDF
导出
摘要 目的:了解沙库巴曲缬沙坦致不良反应发生的情况及特点,为临床安全用药提供参考。方法:检索有关沙库巴曲缬沙坦不良反应的相关文献,对患者的性别、年龄、原患疾病、药物使用情况及不良反应临床表现、处理、转归等数据进行汇总并统计分析。结果:沙库巴曲缬沙坦所致不良反应的个案报道共13例,均来自国外期刊。其中男性12例,女性1例,均为合并其他基础疾病的老年患者;不自主肌肉运动3例、心律失常6例、深度血管麻痹1例、T波过度敏感导致心悸1例、横纹肌溶解1例以及小肠肠梗阻1例;停药后症状好转12例,未好转1例;预后良好6例,预后较差7例。结论:使用沙库巴曲缬沙坦时应加强用药监测,警惕不良反应的发生,以便及时进行对症处理。 Objective: To investigate the characteristics of adverse drug reactions (ADRs) induced by sacubitril/valsartan in order to provide references for safety drug use. Methods: Literature about ADRs caused by sacubitril/valsartan was searched and summarized. The gender, age, original disease, drug use, clinical manifestation, treatment and outcome of the patients with those ADRs were analyzed statistically. Results: Thirteen cases were found which were published as case report in foreign journals. Among them, 12 cases were male and 1 case was female. All the patients were elderly patients with other co-existing diseases. There were 3 cases of involuntary muscle movement, 6 cases of arrhythmia, 1 case of serious vasoparalysis, 1 case of palpitations caused by over-sensitive T-wave, 1 case of rhabdomyolysis, and 1 case of small bowel obstruction. After withdrawal, 12 patients improved while 1 patient did not. The prognosis was good in 6 patients and poor in 7 patients. Conclusion: Physicians and pharmacists should pay more attentions to the safety monitoring of sacubitril/valsartan during medication and be alert to the occurrence of ADRs in order to deal with them in time.
作者 宋兆芮 王相峰 宋燕青 李艳娇 SONG Zhao-rui;WANG Xiang-feng;SONG Yan-qing;LI Yan-jiao(Department of Pharmacy,the First Hospital of Jilin University,Changchun 130021,China)
出处 《中国药物应用与监测》 CAS 2019年第5期283-286,共4页 Chinese Journal of Drug Application and Monitoring
关键词 沙库巴曲缬沙坦 药品不良反应 文献分析 Sacubitril/valsartan Adverse drug reaction Literature analysis
  • 相关文献

参考文献2

二级参考文献11

  • 1金振一,李华,丁大植,秦孝智,崔兰,沈铁宽.缬沙坦联合培哚普利治疗慢性充血性心力衰竭的临床疗效及安全性[J].中国心血管病研究,2004,2(8):608-610. 被引量:2
  • 2陈华茜,刘巍,黄云芳,赵黎,杨涛.大剂量缬沙坦治疗慢性肾病的安全性研究[J].医药导报,2006,25(8):785-787. 被引量:3
  • 3GUTHRIE R. Recent advances in cardiovascular risk reduction: implications of ONTARGET [ J ]. Clin Cornerstone, 2009, 9 ( Suppl 3 ) : S18 - S26.
  • 4BISSESSOR N, WHITE H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction [J].Vasc Health Risk Manag, 2007,3 (4) :425 - 430.
  • 5MESSERLI FH, GROSSMAN E. Therapeutic controversies in hypertension [ J ]. Semin Nephrol,2005,25 (4) :227 - 235.
  • 6FERRI C, CROCE G, Desideri G. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine[J]. Adv Ther, 2008,25(4) :300 -320.
  • 7BASILE G, VILLARI D, GANGEMI S, et al. Candesartan cilexetil-induced severe hepatotoxicity[ J]. J Clin Gastroenterol, 2003,36(3) :273 -275.
  • 8BOSCH X. Losartan-induced hepatotoxicity[J].JAMA, 1997, 278(19) :1572.
  • 9ANDRADE RJ, LUCENA MI, FERNANDEZ MC, et al. Cholestatic hepatitis related to use of irbesartan : a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity [ J ]. Eur J Gastroenterol ttepatol, 2002,14 ( 8 ) : 887 - 890.
  • 10FRYE CB, PETTIGREW TJ. Angioedema and photosensitive rash induced by valsartan[ J]. Pharmacotherapy, 1998,18 (4) : 866 - 868.

共引文献60

同被引文献13

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部